Affymax Files $100M Mixed Securities Shelf
The registration allows for future sales in any combination of common stock, preferred stock, debt securities, warrants and units.
The company is developing Hematide, which will be used to treat anemia related to chronic renal failure. It is the company's only current drug candidate.
Affymax intends to...
To view the full article, register now.